Skip to content
value.today

Attovia Therapeutics, Inc.

ATTO
No market cap data
Compare
World rank
—
no current market cap
Revenue
—
annual
Net income
—
Employees
—

Attovia Therapeutics, Inc. in brief

Attovia Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Carlos, California, USA. Its shares trade under the symbol ATTO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Attovia Therapeutics, Inc. timeline

2 events, 2025–2026
  1. 2025
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2026
  4. 🔔
    Initial public offering
    Final prospectus filed with the SEC on 5 August 2026; shares registered for exchange trading on 29 July 2026.

Events of Attovia Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Mar 2025: revenue —, net income $-15M—Mar ’25Three months to Jun 2025: revenue —, net income $-14M—Jun ’25Three months to Sep 2025: revenue $0M, net income $-14M$0MSep ’25Three months to Mar 2026: revenue —, net income $-19M—Mar ’26Three months to Jun 2026: revenue $0M, net income $-21M$0MJun ’26Three months to Sep 2026: revenue —, net income $-22M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-22M.

SEC filings

Official filings of Attovia Therapeutics, Inc. with the US Securities and Exchange Commission.

Balance sheet

Total assets
$166 M
Total liabilities
$15 M
Total equity
$-107 M

As of December-2025

Top 64 institutional investors in Attovia Therapeutics, Inc.#

As of Sep 30, 2026
64 institutions held 40.1 M shares (about 87.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 63.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Attovia Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Frazier Life Sciences Management, L.P.7,046,271New15.44%$121 MNov 16, 2026
2Goldman Sachs Group Inc5,391,772New11.81%$92 MNov 16, 2026
3venBio Partners LLC4,181,366New9.16%$72 MNov 16, 2026
4Deep Track Capital, LP3,207,138New7.03%$55 MNov 16, 2026
5EcoR1 Capital, LLC2,024,010New4.43%$35 MNov 16, 2026
6Nextech Invest Ltd.1,835,139New4.02%$31 MNov 16, 2026
7Cormorant Asset Management, LP1,788,815New3.92%$31 MNov 16, 2026
8Redmile Group, LLC1,163,587New2.55%$20 MNov 16, 2026
9Commodore Capital LP1,160,000New2.54%$20 MNov 16, 2026
10Sanofi1,082,855New2.37%$19 MNov 5, 2026
11Janus Henderson Group Ltd.1,000,000—2.19%$17 MNov 16, 2026
12Marshall Wace, LLP898,980New1.97%$15 MNov 13, 2026
13Vanguard Capital Management LLC782,012New1.71%$13 MNov 13, 2026
14Federated Hermes, Inc.700,000New1.53%$12 MNov 12, 2026
15Woodline Partners LP686,746New1.50%$12 MNov 16, 2026
16Nantahala Capital Management, LLC561,180New1.23%$10 MNov 13, 2026
17Adage Capital Partners GP, L.L.C.500,000New1.10%$9 MNov 16, 2026
18Millennium Management LLC476,261New1.04%$8 MNov 16, 2026
19Citadel Advisors LLC466,773New1.02%$8 MNov 16, 2026
20Balyasny Asset Management L.P.459,297New1.01%$8 MNov 16, 2026
21Integral Health Asset Management, LLC450,000New0.99%$8 MNov 16, 2026
22Blackstone Inc.339,920New0.74%$6 MNov 16, 2026
23FMR LLC323,669New0.71%$6 MNov 10, 2026
24Vivo Capital, LLC300,000New0.66%$5 MNov 13, 2026
25BlackRock, Inc.265,397New0.58%$5 MNov 13, 2026
Show all 64: investors 26 to 64
Institutional investors 26 to 64 in Attovia Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Spruce Street Capital LP228,295New0.50%$4 MNov 13, 2026
27Braidwell LP225,000New0.49%$4 MNov 16, 2026
28Geode Capital Management, LLC206,176New0.45%$4 MNov 6, 2026
29Boxer Capital Management, LLC200,000New0.44%$3 MNov 16, 2026
30Kalehua Capital Management LLC200,000New0.44%$3 MNov 13, 2026
31UBS Group AG183,751New0.40%$3 MNov 10, 2026
32Jones Hill Capital LP182,295New0.40%$3 MNov 13, 2026
33Point72 Asset Management, L.P.180,664New0.40%$3 MNov 16, 2026
34Stempoint Capital LP138,200New0.30%$2 MNov 16, 2026
35Cantor Fitzgerald, L. P.133,959New0.29%$2 MNov 16, 2026
36Burkehill Global Management, LP120,000New0.26%$2 MNov 16, 2026
37Freestone Grove Partners LP120,000New0.26%$2 MNov 16, 2026
38Charles Schwab Investment Management Inc114,952New0.25%$2 MNov 16, 2026
39Vanguard Fiduciary Trust Co109,177New0.24%$2 MNov 13, 2026
40Ghisallo Capital Management LLC105,000New0.23%$2 MNov 16, 2026
41Seven Grand Managers, LLC90,000New0.20%$2 MNov 16, 2026
42Two Sigma Investments, LP54,828New0.12%$1 MNov 16, 2026
43Squarepoint Ops LLC42,725New0.09%$1 MNov 9, 2026
44LMR Partners LLP40,000New0.09%$1 MNov 16, 2026
45Northern Trust Corp39,287New0.09%$1 MNov 16, 2026
46Morgan Stanley38,451New0.08%$1 MNov 13, 2026
47HRT Financial LP30,868New0.07%$1 MNov 13, 2026
48State Street Corp24,250New0.05%$0 MNov 12, 2026
49Schonfeld Strategic Advisors LLC22,243New0.05%$0 MNov 16, 2026
50Vanguard Portfolio Management LLC20,495New0.04%$0 MNov 13, 2026
51Jump Financial, LLC16,594New0.04%$0 MNov 13, 2026
52Walleye Capital LLC15,107New0.03%$0 MNov 13, 2026
53Legal & General Group Plc15,000New0.03%$0 MNov 16, 2026
54Landscape Capital Management, L.L.C.14,806New0.03%$0 MNov 10, 2026
55ExodusPoint Capital Management, LP13,576New0.03%$0 MNov 16, 2026
56D. E. Shaw & Co., Inc.10,058New0.02%$0 MNov 16, 2026
57Soleus Capital Management, L.P.10,000New0.02%$0 MNov 16, 2026
58Diadema Partners LP9,700New0.02%$0 MNov 16, 2026
59Aster Capital Management (DIFC) Ltd7,774New0.02%$0 MNov 12, 2026
60Vanguard Global Advisers, LLC6,602New0.01%$0 MNov 13, 2026
61Allworth Financial LP4,000New0.01%$0 MNov 17, 2026
62Persistent Asset Partners Ltd2,465New0.01%$0 MNov 13, 2026
63Citigroup Inc1,237New0.00%$0 MNov 4, 2026
64Osaic Holdings, Inc.180New0.00%$0 MNov 12, 2026

Insider trading at Attovia Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$42.1 M
9 purchases, 6 insiders
Sold, 12 months
$2.3 M
46 sales, 2 insiders
Net, 12 months
$39.8 M
open market only
Insiders on file
8
since
Attovia Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Goldman Sachs Asset Management, L.P.Former 10% OwnerConversionindirect · amended+1.96 M——2.04 MForm 4/A
filed Colin WalshDirectorConversionindirect · amended+1.96 M——2.04 MForm 4/A
filed Goldman Sachs Asset Management, L.P.Former 10% OwnerConversionindirect · amended+478,498——2.52 MForm 4/A
filed Colin WalshDirectorConversionindirect · amended+478,498——2.52 MForm 4/A
filed Goldman Sachs Asset Management, L.P.Former 10% OwnerBuyindirect · amended+500,000$17.00—3.02 MForm 4/A
filed Colin WalshDirectorBuyindirect · amended+500,000$17.00—3.02 MForm 4/A
filed Goldman Sachs & Co. LLCFormer 10% OwnerConversionindirect+1.96 M——2.04 MForm 4
filed Colin WalshDirectorConversionindirect+1.96 M——2.04 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Attovia Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.6 M
4.5 days to cover
Shares sold short, last 6 reportsAll stocks →

IPO: priced at $17.00, raising $289M · IPO calendar

Fails to deliver

  • : 222 shares at $15.00
  • : 461 shares at $14.50
  • : 391 shares at $13.73
  • : 3,979 shares at $14.78
  • : 180 shares at $14.96

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Attovia Therapeutics, Inc. scorecard#

Passes 1 of the 1 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growthnot known
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitabilitynot known
    • –Profitable in the newest yearNo net income on file.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 1
    • ✓Short-term assets cover short-term liabilities14.2×Current ratio 14.20 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Events at Attovia Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Bylaws or fiscal year changed 1 · Results announced 2

Attovia Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Attovia Therapeutics, Inc.🇺🇸————
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Balance sheet:
As of December-2025
Profile updated:
Nov 15, 2026

Figures from value.today research, SEC filing; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Attovia Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Attovia Therapeutics, Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Attovia Therapeutics, Inc.? Suggest a correction